Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

890.31 -6.69 (-0.75%)
Streaming Delayed Price Updated: 11:50 AM EDT, Mar 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Novo Nordisk Stock Investors Just Got Great News From Eli Lilly ↗
But it's good news for Eli Lilly, too. 
Via The Motley Fool
News headline image
Is Pfizer Stock an Underrated Healthcare Investment Play? ↗
Pfizer is playing catch-up in the GLP-1 drug space, but the drugmaker has a long history of success. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins ↗
Wall Street is overly focused on GLP-1 drugs even as this medical device maker continues to thrive. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Eli Lilly Breaks New Ground In Crohn's Disease Treatment ↗
Eli Lilly (LLY) reports landmark Phase 3 data for Omvoh, showing over 90% of Crohn's disease patients achieved 3-year steroid-free remission. 
Via Benzinga
News headline image
Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash? ↗
New products are already generating growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing ↗
Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s... 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Market-Beating Stocks to Consider Right Now
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the... 
Via StockStory
News headline image
2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗
These biotech companies have catalysts ahead. 
Via The Motley Fool
News headline image
Warning: This Skyrocketing Stock Has a Hidden Risk ↗
Eli Lilly is leading the pack in the GLP-1 weight-loss drug market, but this good news won't last forever. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Prediction: Eli Lilly Stock Could Surge 45% This Year ↗
Eli Lilly just delivered explosive growth, and analysts see up to 45% upside, but is this pharma giant still a buy at its current price? 
Via The Motley Fool
News headline image
Overlooked and Undervalued: Why Novo Nordisk Stock Deserves Attention ↗
Novo Nordisk looks attractively priced even though 2026 is likely to be a tough year. 
Via The Motley Fool
News headline image
Is Viking Therapeutics Stock Really Going to $125? ↗
Never say never. There's certainly a mathematical path to that level, if the company navigates it correctly. 
Via The Motley Fool
News headline image
3 Stocks to Buy and Hold for 2026 and Beyond ↗
Any of these three pharmaceutical titans could move the needle in your portfolio. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
Pfizer’s BRAFTOVI BREAKWATER Trial Delivers Landmark Survival Gains in Colorectal Cancer
NEW YORK — Pfizer Inc. (NYSE: PFE) has announced breakthrough results from its Phase 3 BREAKWATER clinical trial, demonstrating that its BRAFTOVI (encorafenib) regimen significantly improves both... 
Via MarketMinute
News headline image
Forget Ozempic: This Obesity‑Drug Giant Is Grabbing the Biggest Slice of the GLP‑1 Gold Rush ↗
Ozempic's rival is generating blockbuster revenue and gaining market share. 
Via The Motley Fool
News headline image
Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral. 
Via Stocktwits
Topics ETFs Economy Government
News headline image
2 High-Flying Stocks on Our Buy List and 1 Facing Challenges
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly... 
Via StockStory
Topics Firearms
News headline image
Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 15 Years ↗
 
Via Benzinga
News headline image
Eli Lilly's Landmark Trial Shows Major Psoriasis-Obesity Breakthrough With Taltz-Zepbound Combo ↗
Eli Lilly's latest trial results and new licensing agreement show promise in treating psoriasis, obesity, and kidney disease. 
Via Benzinga
News headline image
Health Care Sector (XLV) Shows Resilience Amid Tech Volatility and Strong Jobs Data
As the broader market grappled with a violent valuation reset in the technology sector, the health care industry emerged as a critical anchor for investors in early 2026. The Health Care Select Sector... 
Via MarketMinute
Topics Artificial Intelligence ETFs Earnings
News headline image
The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth
In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion... 
Via MarketMinute
Topics Earnings Economy
News headline image
Should You Buy the Vanguard S&P 500 ETF With the Stock Market Near a Record High? History Offers a Clear Answer ↗
Despite recent volatility, trends like artificial intelligence could fuel another strong year for the stock market. 
Via The Motley Fool
Topics Artificial Intelligence ETFs Stocks
News headline image
Agios Stock Down 16% in a Year as Fund Cuts Stake by $5.6 Million After 50% November Crash ↗
Agios Pharmaceuticals targets rare blood disorders with a marketed anemia drug and a focused clinical-stage pipeline. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cogent Biosciences Stock Soars 346% in a Year, but One Fund Just Sold Off $4.5 Million ↗
This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Structure Therapeutics Stock Up 187% in One Year as Fund Trims $8 Million From Stake ↗
Structure Therapeutics develops oral therapies for chronic diseases, using a proprietary platform to target G-protein-coupled receptors. 
Via The Motley Fool
News headline image
Kymera Therapeutics Stock Up 120% in 1 Year as Fund Adds $3 Million More ↗
Kymera Therapeutics develops targeted protein degradation therapies for immunology and oncology, advancing multiple clinical-stage programs. 
Via The Motley Fool
News headline image
1 Reason I'd Buy Eli Lilly Stock and Never Sell ↗
A robust pipeline is essential for a buy-and-hold pharmaceutical stock. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Biotechnology Renaissance: AI and Capital Collide in a Multi-Trillion Dollar Pivot
As of February 17, 2026, the biotechnology sector is undergoing its most significant structural transformation in decades, a period now widely termed the "Biotechnology Renaissance." Following a... 
Via MarketMinute
Topics Artificial Intelligence Economy Initial Public Offering
News headline image
NVO Stock Generates Retail Buzz After European Commission Approves 7.2 MG Once-Weekly Dose Of Wegovy Injection ↗
The approval follows a positive recommendation from the European Medicines Agency and is supported by data from clinical trials involving more than 1,400 participants. 
Via Stocktwits
Topics Lawsuit
News headline image
Hims & Hers Faces New Hurdle In Weight-Loss Brawl With Novo Nordisk ↗
Novo Nordisk and the FDA are both mounting pressure on Hims & Hers Health and other GLP-1 compounders. 
Via Investor's Business Daily
Topics Lawsuit
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.